Catalog No.
Product Name
Application
Product Information
Citations
-
Dopamine Receptor Inhibitor
7-Hydroxy-DPAT hydrobromide is a selective agonist for the D3 dopamine receptor, primarily impacting dopamine signaling pathways. This compound demonstrates significant biological activity in modulating locomotor behavior and influencing dopamine metabolism within the central nervous system. It serves as a valuable tool for research applications related to neuropharmacology and the study of dopamine-related disorders. -
Dopamine Receptor Agonist
Talipexole is a selective dopamine receptor agonist primarily targeting D2-like receptors. It is proposed for use as an antiparkinsonian agent, demonstrating potential in improving motor function in Parkinson's disease models. Research applications include studying dopaminergic signaling pathways and exploring therapeutic options for neurodegenerative disorders. -
D3 Receptor Antagonist
Mesdopetam hemitartrate is a selective antagonist of the dopamine D3 receptor, exhibiting a Ki value of 90 nM and an IC50 of 9.8 μM for human recombinant D3 receptors. This compound demonstrates psychomotor stabilizing effects, making it a valuable tool in the investigation of motor and psychiatric complications associated with Parkinson's disease. Its unique properties contribute to research aimed at understanding the underlying mechanisms of dopamine-related disorders. -
Dopamine D3 Receptor Antagonist
Mesdopetam is a selective antagonist of the dopamine D3 receptor, displaying a Ki value of 90 nM and an IC50 of 9.8 μM for the human recombinant D3 receptor. This compound exhibits psychomotor stabilizing properties and is utilized in research focused on motor and psychiatric complications associated with Parkinson's disease. Its role in modulating dopamine signaling makes it valuable for studying therapeutic strategies in this context. -
DRD4 Antagonist
PD 168568 dihydrochloride is a potent and orally active antagonist of the dopamine receptor D4 (DRD4). This compound exhibits selectivity for the D4 receptor, with Ki values of 8.8 nM for DRD4 compared to 1842 nM for DRD2 and 2682 nM for DRD3. PD 168568 dihydrochloride is applicable in glioblastoma (GBM) research, making it a valuable tool for investigating the role of DRD4 in cancer biology and potential therapeutic strategies. -
Dopamine
AJ-76 hydrochloride is a potent antagonist of dopamine autoreceptors, exhibiting pKi values of 6.95, 6.67, 6.37, 6.21, and 6.07 for human D3, D4, D2 short, D2 long, and rat D2 receptors, respectively. This compound is valuable for research focused on dopamine receptor modulation and its implications in neurological disorders. Its specific receptor affinity allows for investigations into the roles of dopamine signaling in various physiological and pathological processes. -
Dopamine Receptor Inhibitor
GBR 12783 is a selective dopamine uptake inhibitor that targets dopamine receptors with high potency. It effectively inhibits [3H]dopamine uptake in striatal synaptosomes from rats and mice, exhibiting IC50 values of 1.8 nM and 1.2 nM, respectively. This compound has been shown to enhance memory performance and increase hippocampal acetylcholine release in rodent models, making it valuable for research in neuropharmacology and cognitive function studies. -
Dopamine Receptor Antagonist
Zuclopenthixol dihydrochloride is a thioxanthene derivative that functions as a mixed antagonist of dopamine D1 and D2 receptors. This compound is primarily utilized in schizophrenia research, aiding in the investigation of neurochemical pathways associated with the disorder. Its ability to modulate dopaminergic signaling makes it a valuable tool for studying the efficacy of antipsychotic therapies. -
Dopamine D3 Receptor Antagonist
(-)-GSK598809 hydrochloride is a potent and selective antagonist of the dopamine D3 receptor (DRD3). It exhibits high affinity for DRD3, making it a valuable tool for studying dopamine-related pathways and their implications in neuropsychiatric disorders. This compound is suitable for research applications focused on drug development, behavioral studies, and understanding the role of dopamine in various physiological processes. -
Dopamine Receptor Antagonist
RG-15 is a potent oral antagonist of the dopamine receptors, specifically targeting the human D2 and D3 receptors with pKi values of 8.23 and 10.49, respectively. It effectively inhibits dopamine-stimulated [35S]GTPγS binding, demonstrating an IC50 of 21.2 nM in rat striatal membranes, 36.7 nM in mouse A9 cells expressing human D2L receptors, and 7.2 nM in CHO cells expressing human D3 receptors. RG-15 also enhances dopamine turnover and biosynthesis in the mouse striatum and olfactory bulb, indicating potential antipsychotic properties. This compound is valuable for research into dopamine-related disorders and therapeutics. -
Dopamine D3 Receptor Antagonist
Nafadotride is a selective antagonist of the dopamine D3 receptor. By inhibiting dopamine D3 receptor activity, Nafadotride modulates dopamine signaling pathways that are critical for regulating emotion, motivation, reward, and motor functions. This compound is suitable for research into the role of dopamine D3 receptors in neuropsychiatric disorders and behavior-related studies, providing insights into potential therapeutic targets. -
Dopamine D3/D2 Receptor Agonist
Quinelorane dihydrochloride is a potent agonist of the dopamine D3 and D2 receptors, facilitating modulation of dopaminergic signaling pathways. This compound shows promise in the investigation of neurological and psychiatric disorders, offering valuable insights into the mechanistic underpinnings of related conditions. Research applications may include studies on dopamine receptor function, neuropharmacology, and potential therapeutic interventions. -
D3 Receptor Antagonist
U-99194 maleate is a potent and selective antagonist of the dopamine D3 receptor, exhibiting a Ki value of 160 nM. This compound effectively inhibits both endogenously released dopamine and exogenous D3 agonist activation of the D3 receptor. In rat hippocampal slices, U-99194 maleate reverses the IPSC-suppressive effect induced by the D3 agonist PD 128907. Additionally, it demonstrates significant suppression of nicotine-induced tremors in mouse models, making it a valuable tool for investigating dopamine D3 receptor-mediated motor disorders, particularly in the context of kinetic tremors. -
Dopamine Receptor Blocker
Dicarbine dihydrochloride is a dopamine receptor antagonist that modulates neurotransmission within multiple regions of the brain. By blocking dopamine receptors, it effectively mitigates the suppression of conditioned defense reflexes induced by stimulation of the mesencephalic reticular formation. This compound serves as a valuable tool in research addressing schizophrenia and alcoholic psychosis, facilitating insights into dopamine-related pathophysiology and therapeutic interventions. -
Dopamine Receptor Inhibitor
Cyclo(glycyl-L-leucyl) is a neuropeptide that specifically inhibits dopamine receptors, playing a crucial role in modulating dopaminergic signaling. This compound has been shown to down-regulate dopamine receptor activity and reduce dopaminergic supersensitivity, particularly in the context of morphine-induced analgesia in animal models. Cyclo(glycyl-L-leucyl) holds promise for potential therapeutic applications in preventing tardive dyskinesias and L-DOPA-induced dyskinesias, making it valuable for research in neuropharmacology and movement disorders. -
D2 Receptor Agonist
Carmoxirole hydrochloride is a selective agonist of the dopamine D2 receptor, demonstrating significant peripheral activity. It is primarily used in research related to antihypertensive mechanisms and cardiovascular physiology. This compound is valuable for studies exploring dopamine receptor signaling and its implications in blood pressure regulation. -
D2 Receptor Antagonist
Alizapride is a selective antagonist of the D2 dopamine receptor, primarily used for its potent antiemetic properties. It exhibits effectiveness in managing nausea and vomiting, and is also applicable in the treatment of various human digestive disorders. Research involving Alizapride contributes to the understanding of dopamine's role in gastrointestinal function and the development of therapeutic strategies for related conditions. -
Dopamine Receptor Ligand
(-)-Isocorypalmine is a potent ligand for dopamine receptors, specifically isolated from the crude base fraction of Corydalis chaerophylla. This compound demonstrates high affinity, with a Km value of 4.63 ± 0.71 μM, as confirmed by recombinant CYP719A21. It holds significant promise for research in neuropharmacology and studies related to dopamine signaling pathways. -
Dopamine Receptor Antagonist
Moperone is a potent antagonist of D2 and D3 dopamine receptors, with IC50 values of 1.0 nM for both targets. This compound exhibits significant biological activity in the modulation of dopaminergic signaling pathways, making it a valuable tool for research into psychiatric disorders and neurological conditions. Moperone is particularly useful in studies examining the role of dopamine receptors in behavior and cognition. -
Psychoactive Substance
MFZ 2-13 is an N-demethylated intermediate and N-nor-analogue of MFD 2-12 that targets the human dopamine receptor. It functions as an inhibitor of dopamine uptake, exhibiting an IC50 of 1.4 nM. This compound is valuable for research in neuropharmacology and the study of psychoactive substances. -
Dopamine Receptor Antagonist
A-437203 is a selective antagonist for the dopamine D3 receptor, exhibiting Ki values of 71 nM for D2, 1.6 nM for D3, and 6220 nM for D4 receptors. This compound is valuable for research into dopamine-related pathways and offers potential applications in studying neuropsychiatric disorders. Its specificity for the D3 receptor makes it a useful tool for exploring the role of this receptor in various biological processes and assessing new therapeutic strategies. -
Dopamine D2 Receptor Agonist
Aplindore is a potent dopamine D2 receptor agonist, exhibiting a pKi value of 9.1. This compound is significant in the study of Parkinson's disease, as it aids in elucidating dopaminergic signaling pathways. Its activity provides valuable insights into therapeutic strategies for managing symptoms associated with dopaminergic deficits. -
Dopamine Receptor Agonist
Matsupexolum is a dopamine receptor agonist that selectively activates dopamine receptors, facilitating neurotransmission. This compound demonstrates significant biological activity in modulating dopaminergic signaling pathways and can be utilized in research focused on neuropharmacology, psychiatry, and the study of movement disorders. Its application may provide insights into the therapeutic potential for conditions such as schizophrenia and Parkinson's disease. -
Dopamine Receptor Modulator
Glovadalenum is a positive allosteric modulator of the dopamine D1 receptor. This compound enhances dopamine receptor signaling, making it valuable for research in neuropharmacology and neurodegenerative diseases. Its modulation of dopaminergic pathways offers potential insights into the treatment of conditions such as schizophrenia and Parkinson's disease. -
Stable Isotope
Propionylpromazine-d6 hydrochloride is a deuterium-labeled derivative of Propionylpromazine hydrochloride, a potent dopamine receptor D2 (DRD2) antagonist. This reagent is primarily utilized in pharmacological research focusing on Parkinson's disease, enabling the study of dopamine signaling pathways and receptor interactions. The stable isotope labeling provides enhanced analytical precision, making it suitable for advanced bioanalytical applications. -
Dopamine D2/D3 Receptor Antagonist
Trazpiroben is a selective antagonist of the dopamine D2 and D3 receptors, primarily utilized for investigating the pathophysiology and treatment of moderate-to-severe gastroparesis. Its inhibition of these receptors plays a significant role in regulating gastrointestinal motility. Trazpiroben is a valuable tool for researchers exploring the therapeutic potential and underlying mechanisms of dopamine-related gastrointestinal disorders. -
Dopamine Receptor Inhibitor
Fosopamine hydrochloride is a dopamine receptor D agonist, primarily targeting the dopamine receptor pathways. It has demonstrated significant utility in research related to hypertension, aiding in the exploration of cardiovascular mechanisms and blood pressure regulation. This compound may provide insights into both the physiological and pathological roles of dopamine signaling in hypertension-related studies. -
Dopamine Agonist
PD 120697 is an orally active dopamine agonist that primarily targets dopamine receptors. It exhibits significant inhibition of striatal dopamine synthesis and reduces dopaminergic neuronal firing, leading to decreased spontaneous locomotor activity. PD 120697 also effectively reverses depression induced by Reserpine, making it a valuable tool for studying dopamine-related disorders and potential therapeutic interventions. -
D2 Receptor Antagonist
Eticlopride is a selective antagonist of the dopamine D2 receptor, demonstrating a high binding affinity for dopamine D2 as well as for α1-adrenergic, α2-adrenergic, 5HT1, and 5HT2 receptors, with Kis of 0.09, 112, 699, 6220, and 830 nM, respectively. This compound is primarily utilized in research related to antipsychotic drug development and elucidation of dopamine's role in neuropsychiatric disorders. Its pharmacological profile supports investigations into dopamine receptor modulation and its implications in various neurological conditions. -
D3 Receptor Ligand
Dopamine D3 receptor ligand-3 is a selective ligand for the D3 receptor, exhibiting a high affinity with a Ki value of 3.6 nM. This compound demonstrates significant selectivity for the D3 receptor over the D2 receptor, with a Ki of 353 nM. It serves as a valuable tool for research applications focusing on dopaminergic signaling and related neurological disorders. -
Dopamine Receptor Inhibitor
PD 128907 is a selective dopamine D3 receptor inhibitor that effectively modulates dopaminergic signaling. The active (+) enantiomer exhibits high affinity for rat D3 receptors and demonstrates significant inhibitory effects on neuronal firing in the ventral tegmental area and substantia nigra pars compacta, with EC50 values of 33 nM and 38 nM, respectively. Additionally, it inhibits dopamine release in the caudate putamen with an EC50 of 66 nM. While PD 128907 primarily targets D3 receptors, evidence suggests its actions may also involve D2 autoreceptors, making it a valuable tool for exploring dopamine receptor pharmacology and neurobehavioral research. -
D2 Agonist
Naxagolide hydrochloride is a selective agonist of the dopamine D2 receptor. This compound exhibits significant dopaminergic activity, making it valuable in research focused on Parkinsonism and related movement disorders. It serves as a potential therapeutic agent for understanding the modulation of dopaminergic signaling in neurological studies. -
Dopamine Agonist
CGS 15873A is an orally active benzopyranopyridine derivative that functions as a selective dopamine agonist. This compound activates dopamine receptors, making it valuable for studying the physiological and pharmacological roles of dopamine in the central nervous system. CGS 15873A is particularly relevant in research related to neurological disorders such as schizophrenia and Parkinson's disease. -
D3 Receptor Antagonist
FAUC 365 is a highly selective antagonist for the dopamine D3 receptor, exhibiting a Ki value of 0.5 nM. It demonstrates significantly lower binding affinities at D4.4, D2short, and D2Long receptors, with Ki values of 340 nM, 2600 nM, and 3600 nM, respectively. FAUC 365 is primarily utilized in research related to schizophrenia and Parkinson's disease, providing valuable insights into dopamine receptor interactions and potential therapeutic interventions. -
Dopamine D3 Receptor Agonist
SK609 hydrochloride is a selective agonist of the dopamine D3 receptor, exhibiting an EC50 of 1109 nM. This compound demonstrates significant biological activity in modulating dopamine signaling pathways, making it a valuable tool in Parkinson's disease research. Its unique properties facilitate the exploration of D3R-related mechanisms, contributing to the understanding of dopaminergic dysfunction in neurodegenerative disorders. -
Dopamine Receptor Modulator
Raxlaprazine etomoxil is a small molecule compound that functions as a dopamine D2 and D3 receptor modulator. This compound shows high affinity for human recombinant D2L receptors, with an inhibition constant (Ki) of 1.95 nM, and effectively inhibits forskolin-stimulated cAMP accumulation with a half maximal effective concentration (EC50) of 3.72 nM. Raxlaprazine etomoxil is valuable for research focused on mental illnesses and neurological disorders. -
Dopamine D3 receptor ligand
Dopamine D3 receptor ligand-1 is a potent and selective ligand for the dopamine D3 receptor, exhibiting a high affinity with a Ki value of 8 nM. This compound demonstrates an impressive 89-fold selectivity for the D3 receptor over the D2 receptor (D2 Ki = 715 nM). Its specificity makes it a valuable tool for investigating the D3 receptor's role in various neurobiological processes and for drug discovery efforts targeting dopamine-related disorders. -
Dopamine Receptor Inhibitor
ADTN is a dopamine receptor inhibitor that modulates dopamine neurotransmission. It demonstrates the ability to reduce dopamine-related signaling, which may help target conditions associated with excessive dopamine activity. ADTN is applicable in research focused on mental health disorders and cognitive function modulation, providing insights into therapeutic strategies for related pathologies. -
Dopamine D2/D3 Agonist
D-520 is a potent dopamine D2/D3 receptor agonist, demonstrating an EC50 of 4.73 nM and 2.18 nM for D2 and D3 receptors, respectively. This compound exhibits significant inhibitory effects on the formation of amyloid-beta (Aβ) aggregates and facilitates the disaggregation of both alpha-synuclein and Aβ aggregates in vitro. D-520 shows promising efficacy in animal models of Parkinson's disease, making it a valuable tool for research in Parkinson's disease and dementia associated with Parkinson’s disease. -
Stable Isotope
Pramipexole-d5 is a deuterium-labeled derivative of Pramipexole, a selective dopamine D2-type receptor agonist that effectively crosses the blood-brain barrier. With binding affinities (Kis) of 2.2 nM, 3.9 nM, 0.5 nM, and 1.3 nM for the D2-type, D2, D3, and D4 receptors respectively, Pramipexole-d5 serves as a valuable tool for exploring dopamine receptor interactions. This compound is particularly relevant for research into neurodegenerative disorders such as Parkinson's disease and conditions like restless legs syndrome. -
Dopamine Receptor Inhibitor
Metoclopramide dihydrochloride is a dopamine D2 receptor antagonist primarily used for its antiemetic effects. It demonstrates notable activity in managing nausea and vomiting, particularly in patients undergoing chemotherapy or surgery. This compound is also employed in research settings to explore the modulation of dopaminergic pathways and gastrointestinal motility. -
Dopamine Receptor Agonist
PF2562 is a selective agonist of the dopamine D1 receptor, demonstrating a binding affinity with a Ki of 113 nM. It effectively stimulates cAMP production in human D1 receptor assays, exhibiting an EC50 value of 568 nM in HTRF assays. This compound is valuable for research applications involving dopamine receptor signaling and related neurological studies. -
Dopamine Receptor
SK609 is a selective agonist of the dopamine D3 receptor, enhancing dopamine and norepinephrine levels in the cerebral cortex. This compound has demonstrated efficacy in suppressing dyskinesias in preclinical models of Parkinson's disease and alleviating muscle twitches caused by L-dopa treatment. Additionally, SK609 has been shown to improve performance in sustained attention tasks by significantly reducing both misses and false alarms. Research indicates that SK609 may offer therapeutic potential for mitigating movement and cognitive deficits associated with Parkinson's disease. -
Dopamine D2 Ligand
UNC0006 is a β-arrestin-biased ligand targeting the dopamine D2 receptor. This compound is primarily utilized in the investigation of antipsychotic mechanisms and their effects on dopamine signaling pathways. Its unique bias towards β-arrestin pathways may offer new insights into therapeutic strategies for psychiatric disorders. -
D2 Receptor Antagonist
Y-20024 hydrochloride is a selective D2 receptor antagonist known for its ability to cross the blood-brain barrier. It effectively inhibits Apomorphine-induced symptoms associated with attention deficit hyperactivity disorder (ADHD) in murine models and also mitigates Apomorphine-induced vomiting in canine subjects. This compound demonstrates prolactin-promoting activity and is valuable for research into neurological disorders such as ADHD and emesis. -
Dopamine Antagonist
Neflumozide is a potent dopamine antagonist classified as a benzisoxazole derivative. It exhibits significant antipsychotic activity, making it a valuable tool for investigating psychosis and related conditions. This compound is useful in preclinical research aimed at understanding dopamine receptor modulation and its implications in psychiatric disorders. -
Dopamine D2 Receptor Antagonist
Tropapride is a selective antagonist of the dopamine D2 receptor. It exhibits significant biological activity by modulating dopaminergic signaling, making it a valuable tool for investigating neurological disorders. This compound is commonly utilized in research focused on conditions such as schizophrenia, Parkinson's disease, and other related neurological dysfunctions. -
Dopamine Receptor Inhibitor
Bulbocapnine hydrochloride is a potent dopamine receptor inhibitor that plays a significant role in modulating dopaminergic activity. This aporphine alkaloid is known to inhibit dopamine synthesis and exhibits neuroleptic-like properties, alongside anticonvulsant and antinociceptive effects. Its pharmacological profile makes it a valuable tool in research related to neurological disorders and the exploration of dopamine-related pathways. -
Dopamine D3 Receptor Agonist
BP 897 is a potent partial agonist of the dopamine D3 receptor and exhibits weak antagonistic activity at the D2 receptor. With a high affinity for the D3 receptor (Ki=0.92 nM) and significantly lower affinity for the D2 receptor (Ki=61 nM), BP 897 is a valuable tool for studying dopaminergic signaling. This compound is primarily used in research related to neuropsychiatric disorders and the role of dopamine receptors in therapeutic contexts. -
Dopamine Receptor
3'-Fluorobenzylspiperone maleate is a selective ligand for dopamine D2 receptors, demonstrating significant potential in the modulation of dopaminergic activity. This compound has been shown to exhibit improved efficacy in alleviating behavioral disorders compared to placebo, making it a valuable tool for research into neuropsychiatric conditions and the pharmacological study of dopamine pathways. Its targeted action underscores its relevance in the investigation of dopamine-mediated therapeutic interventions.
